Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 2, 2008, Pages 506-511

  Corren, Jonathan ^a   Shapiro, Gail ^b   Reimann, James ^c   Deniz, Yamo ^c   Wong, Dennis ^c   Adelman, Daniel ^d   Togias, Alkis ^e  

^a Allergy Research Foundation   (United States)

^b Asthma Inc   (United States)

^c GENENTECH INC   (United States)

^d PHARMACYCLICS INC   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

allergen skin tests; allergic rhinitis; anti IgE; IgE; Omalizumab

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

ADULT; ALLERGENICITY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; BACKACHE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD ALLERGY; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PAIN; PHARYNGITIS; PRIORITY JOURNAL; SKIN ALLERGY; SKIN TEST; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, DERMATOPHAGOIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN E; INJECTIONS, INTRAVENOUS; MALE; RHINITIS, ALLERGIC, PERENNIAL; SKIN TESTS;

EID: 38949120228     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.11.026     Document Type: Article

References (18)

1. Kaliner M.A. Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep 4 (2004) 237-244
2. Belliveau P.P. Omalizumab: a monoclonal anti-IgE antibody. MedGenMed 7 (2005) 27
3. Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 11 (2005) 27-34
4. Walker S., Monteil M., Phelan K., Lasserson T.J., and Walters E.H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2 (2006) CD003559
5. Omalizumab (Xolair). [package insert] (2007), Genentech, Inc, South San Francisco (CA)
6. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., Ren S., et al. Pharmacodynamics of omalizumab: implications for optimized dosing strategies and clinical efficacy in the treatment of asthma. Curr Med Res Opin 19 (2003) 491-498
7. Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., et al., Omalizumab Seasonal Allergic Rhinitis Trial Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286 (2001) 2956-2967
8. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., and Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115 (2005) 459-465
9. Milgrom H., Fick R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341 (1999) 1966-1973
10. Lin H., Boesel K.M., Griffith D.T., Prussin C., Foster B., Romero F.A., et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 113 (2004) 297-302
11. Saini S.S., MacGlashan Jr. D.W., Sterbinsky S.A., Togias A., Adelman D.C., Lichtenstein L.M., et al. Down-regulation of human basophil IgE and FCε{lunate}RIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162 (1999) 5624-5630
12. Casale T.B., Bernstein I.L., Busse W.W., La Force C.F., Tinkelman D.G., Stoltz R.R., et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100 (1997) 110-121
13. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001) 184-190
14. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., and Lichtenstein L.M. Serum IgE level drives basophil and mast cell IgE receptor display. Int Arch Allergy Immunol 113 (1997) 45-47
15. Saini S.S., Klion A.D., Holland S.M., Hamilton R.G., Bochner B.S., and Macglashan Jr. D.W. The relationship between serum IgE and surface levels of FcepsilonR on human leukocytes in various diseases: correlation of expression with FcepsilonRI on basophils but not on monocytes or eosinophils. J Allergy Clin Immunol 106 (2000) 514-520
16. Simons F.E. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 113 suppl 9A (2002) 38S-46S
17. Ong Y.E., Menzies-Gow A., Barkans J., Benyahia F., Ou T.-T., Ying S., et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116 (2005) 558-564
18. Johansson S.G., Oman H., Nopp A., and Pettersson S. The importance of IgE antibody levels in anti-IgE treatment. Allergy 61 (2006) 1216-1219